Metastatic Colorectal Cancer Clinical Trial
— OPTILIVOfficial title:
Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic colorectal cancer through combining systemic cetuximab and hepatic artery infusion of three-drug chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil).
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | December 2015 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
- Histologically or cytologically confirmed carcinoma of the colon and/or rectum with
evidence of liver metastases (new confirmation of metastatic disease is required in
case the time interval from last histological diagnosis to enrolment exceeds 3
years). - Patient with wild type (WT) KRAS tumor status - Patient whose liver metastases are considered to be non resectable with curative intent in medico-surgical staff meeting. In particular patients with at least one of the following criteria, which prevent complete local treatment of liver metastasis with surgery alone or surgery plus radiofrequency ablation because: - less than 30% estimated residual liver after resection - disease in contact with liver main vessels - documented progressive disease on imaging documents or doubling of serum levels of carcino-embryonic antigen (CEA) or CA19.9 over the past 90 days or less - Patient with up to three resectable extrahepatic nodules of <= 10 mm - One, two or three prior chemotherapy lines for colorectal cancer. - Written informed consent. - Age >=18 years. - Patient must be able to comply with the protocol. - Life expectancy of at least 3 months. - At least one measurable metastatic liver lesion (as per RECIST criteria). - World Health Organization performance status of 0 or 1. - Adequate hematological function: absolute neutrophil count (ANC) >=1.0 x 10^9/L; platelets >=75 x 10^9/L, hemoglobin (Hb) >=8.5 g/dL. - International normalized ratio (INR) <=1.5 and activated partial thromboplastin time (aPTT) <=1.5 x upper limit of normal (ULN) within 7 days prior to starting study treatment, in the absence of anticoagulant therapy. - Liver function: serum bilirubin <=1.5 x ULN; alkaline phosphatase and transaminases <5 x ULN (liver metastases). - Serum creatinine <= 1.5 x ULN. - Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile). Exclusion Criteria: - Patient whose primary tumor or metastasis displays mutation of K-Ras (codon 12 and/or 13). - Unresectable extrahepatic diseases. - More than three resectable extrahepatic nodules. - Size of extra hepatic nodules > 1 cm - Prior HAI of the 3 drugs. - More than 2 prior surgical attempts for metastatic disease - Prior radiotherapy for metastatic disease - Known documented intolerance or hypersensitivity to any of the drugs used. - Sensory neuropathy grade 3 (National Cancer Institute-Common Terminology Criteria for Adverse Events -NCI-CTCAE, Version 3.0). - Past or current history (within the last 2 years prior to treatment start) of malignancy other than colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible). - Serious, non healing wound, ulcer, or bone fracture. - Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications. - Pregnancy or lactation - Fertile women (< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception. Prior systemic administration of cetuximab or other anti-EGFR agent is not an exclusion criterion. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Clinique Saint-Joseph | Liège | |
France | CHU de Bordeaux, Hôpital Saint-André | Bordeaux | |
France | Hôpital Ambroise Paré | Boulogne-Billancourt | |
France | Centre Jean Perrin | Clermont-Ferrand | |
France | CHRU de Lille, Hôpital Claude Huriez | Lille | |
France | Hôpital Cochin | Paris | |
France | Hôpital Européen Georges Pompidou | Paris | |
France | CHU Toulouse | Toulouse | |
France | Chronotherapy Unit, Medical Oncology Department, Paul Brousse Hospital | Villejuif | |
France | Institut Gustave Roussy | Villejuif | |
Italy | Università G. d'Annunzio | Chieti | |
Italy | Azienda Ospedaliera S.Maria Degli Angeli | Pordenone | |
Italy | Istituto Regina Elena | Roma | |
Portugal | Hospital Fernando Fonesca | Amadora |
Lead Sponsor | Collaborator |
---|---|
Association pour la Recherche sur le Temps Biologique et la Chronothérapie | CRESGE, Gustave Roussy, Cancer Campus, Grand Paris, Merck Serono International SA, Pfizer |
Belgium, France, Italy, Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy. | evaluation every 6th week up to 18 weeks | No | |
Secondary | The rate and site(s) of relapse in the resected patients throughout the 3-year span that follows hepatectomy | every 2 month up to 3 years | No | |
Secondary | The relapse-free survival in the resected patients | every 2nd month up to 3 years | No | |
Secondary | The progression-free and the overall survival in the patients receiving at least 4 full courses of HAI therapy and in all the patients (intent to treat) | every 2nd month up to 3 years | No | |
Secondary | The objective response rate | every 6 weeks up to 18 weeks | No | |
Secondary | The rate of adverse events | continuous up to 30 days following end of treatment | Yes | |
Secondary | The per-operative and post-operative complications associated to liver surgery | continuous up to 3 months following surgery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01228734 -
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
|
Phase 3 | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Completed |
NCT01591421 -
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05412706 -
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
|
Phase 2 | |
Withdrawn |
NCT04430985 -
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Withdrawn |
NCT03182894 -
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05725200 -
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Terminated |
NCT03176264 -
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
|
Phase 1 | |
Completed |
NCT04866290 -
HepaSphere™ Microspheres Prospective Registry
|
||
Not yet recruiting |
NCT06425133 -
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
|
Phase 2 | |
Not yet recruiting |
NCT05531045 -
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
|
||
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Completed |
NCT02906059 -
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02575378 -
Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer
|
Phase 4 | |
Withdrawn |
NCT02535988 -
Abscopal Effect for Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02848807 -
Chemotherapy-related Toxicity, Nutritional Status and Quality of Life
|
N/A | |
Active, not recruiting |
NCT02077868 -
Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment
|
Phase 3 | |
Completed |
NCT02414009 -
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT01949194 -
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
|
Phase 2 | |
Withdrawn |
NCT01915472 -
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
|
Phase 2 |